IL-6: Insights into novel biological activities

Clinical Immunology and Immunopathology

Volumn 85, Issue 1, 1997, Pages 16-20

  Barton, Beverly E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE DESTRUCTION; CACHEXIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SEPTIC SHOCK; SPLEEN CELL;

EID: 0031260283     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4420     Document Type: Review

References (87)

1. Hirano T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 324:1986;73-76.
2. 2. Proc. Natl. Acad. Sci. USA. 84:1987;3633-3637.
3. Leutz A. Molecular cloning of the chicken myelomonocytic growth factor (cMGF) reveals relationship to interleukin-6 and granulocyte colony stimulating factor. EMBO. 8:1989;175-181.
4. Bazan F. Haemopoietic receptors and helical cytokines. Immunol. Today. 11:1990;350-354.
5. Taga T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 58:1989;573-581.
6. Davis S. LIFRβ and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science. 260:1993;1805-1808.
7. Gearing D. P. The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science. 255:1992;1434-1437.
8. Gearing D. P., Bruce A. G. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol. 4:1992;61-65.
9. Hilton D. J. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J. 13:1994;4765-4775.
10. Yin T. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J. Immunol. 151:1993;2555-2561.
11. Murakami M. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 260:1993;1808-1810.
12. Stahl N. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science. 263:1994;92-96.
13. Kumanogoh A. Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130. Proc. Natl. Acad. Sci. USA. 94:1997;2478-2482.
14. Yoshida K. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. USA. 93:1996;407-411.
15. Jansen J. H. Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells. J. Exp. Med. 175:1992;1151-1154.
16. Dalrymple S. A. IL-6 deficient mice are highly susceptible toL. monocytogenes. Infect. Immun. 63:1995;2262-2268.
17. Suzuki Y. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect. Immun. 65:1997;2339.
18. F. A. Houssiau, P. G. Coulie, D. Olive, J. Van Snick, Synergistic activation of human T cells by interleukin 1 and interleukin 6, Eur. J. Immunol. 18, 1988.
19. 2. Proc. Natl. Acad. Sci. USA. 84:1987;7629-7633.
20. 2. J. Immunol. 141:1988;1556-1562.
21. Lotz M. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med. 167:1988;1253-1258.
22. Cueppens J. L., Baroja M. L., Lorre K., Van Damme J., Billiau A. Human T cell activation with phytohemagglutinin. J. Immunol. 141:1988;3868-3874.
23. 3. J. Leukocyte Biol. 51:1992;237-243.
24. Hudak S. Anti-IL-6 antibodies suppress myeloid cell production and the generation of CFU-c in long term bone marrow cultures. Exp. Hematol. 20:1992;412-417.
25. Ulich T. R., del Castillo J., Guo K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood. 73:1989;108-110.
26. Takai Y., Wong G. G., Clark S. C., Burakoff S. J., Herrmann S. H. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J. Immunol. 140:1988;508-512.
27. Ming J., Cernetti C., Steinman R. M., Granelli-Piperno A. Interleukin-6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium. J. Mol. Cell. Immunol. 4:1989;203-212.
28. Galandrini R. Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function. Cell. Immunol. 138:1991;11-23.
29. Bass H. Z., Yamashita N., Clement L. T. Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. J. Immunol. 151:1993;2895-2903.
30. 2. J. Immunol. 143:1989;1206-1209.
31. Moskowitz N. H., Brown D. R., Reiner S. L. Efficient immunity againstLeishmania major. Infect. Immun. 65:1997;2448-2450.
32. Mihara M., Ikuta M., Koishihara Y., Ohsugi Y. Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur. J. Immunol. 21:1991;2327-2331.
33. Muraguchi A. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167:1988;332-344.
34. Okada M. B cell growth factor (BCGF) and B cell differentiation factor from human T hybridomas. J. Exp. Med. 157:1983;583-590.
35. Takatsuki F. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J. Immunol. 141:1988;3072-3077.
36. Aarden L., Lansdorp P., DeGroot E. A growth factor for B cell hybridomas produced by human monocytes. Lymphokines. 10:1985;175-185.
37. Aarden L., DeGroot E., Schaap O. L., Lansdorp P. Production of hybridoma growth factor by human monocytes. Eur. J. Immunol. 17:1987;1411-1416.
38. Aarden L. A. Hybridoma growth factor. Ann. N.Y. Acad. Sci. 557:1989;192-199.
39. 2. Science. 235:1987;731-732.
40. Suematsu S. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA. 86:1989;7547-7551.
41. Preiser J. C. Interleukin-6 administration has no acute hemodynamic or hematologic effects in the dog. Cytokine. 3:1991;1-4.
42. Neta R., Vogel S. N., Sipe J. D., Wong G. G., Nordan R. P. Comparison ofin vivo. Lymphokine Res. 7:1988;403-412.
43. Asano S. In vivo. Blood. 75:1990;1602-1605.
44. 2. J. Biol. Chem. 266:1991;2647-2651.
45. 2. Can. J. Physiol. Pharmacol. 6:1983;561-566.
46. 2. Agents Actions. 24:1988;320-325.
47. Aderka D., Le J., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143:1989;3517-3523.
48. Aderka D. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α Blood. 81:1993;2076-2084.
49. Ulich T. R., Guo K., Remick D., Del Castillo J., Yin S. Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J. Immunol. 146:1991;2316-2323.
50. Riedy M. C., Stewart C. C. Inhibitory role of interleukin-6 in macrophage proliferation. J. Leukocyte Biol. 52:1992;125-127.
51. Ritchie P. K. Adenosine increases interleukin 6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. Cytokine. 9:1997;187-198.
52. 12in vivo. J. Pharmacol. Exp. Ther. 268:1994;1166-1173.
53. Cronstein B. N., Naime D., Ostad E. The antiinflammatory mechanism of methotrexate. J. Clin. Invest. 92:1993;2675-2682.
54. Chen W., Havell E. A., Gigliotti F., Harmsten A. G. Interleukin-6 production in a murine model ofPneumocystis carinii. Infect. Immun. 61:1993;97-102.
55. Bermudez L. E., Wu M., Petrofsky M., Young L. S. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect. Immun. 60:1992;4245-4252.
56. Denis M. Interleukin-6 in mouse hypersensitivity pneumonitis: Changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. J. Leukocyte Biol. 52:1992;197-201.
57. Ulich T. R. Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am. J. Pathol. 138:1991;1097-1101.
58. Lotz M., Guerne P.-A. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating factor activity (TIMP-1/EPA). J. Biol. Chem. 266:1991;2017-2020.
59. Barton B. E., Jackson J. V. The protective role of IL-6 in a septic shock model. Infect. Immun. 61:1993;1496-1499.
60. Barton B. E., Shortall J., Jackson J. V. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect. Immun. 64:1996;714-718.
61. Baumann H., Onorato V., Gauldie J., Jahreis G. P. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J. Biol. Chem. 262:1987;9756-9768.
62. Baumann H., Strassmann G. Suramin inhibits the stimulation of acute phase protein genes by IL-6-type cytokines in rat hepatoma cells. J. Immunol. 151:1993;1456-1462.
63. Perlstein R. S., Mougey E. H., Jackson W. E., Neta R. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormonein vivo. Lymphokine Cytokine Res. 10:1991;141-146.
64. Salas M. A., Evans S. W., Levell M. J., Whicher J. T. Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin. Exp. Immunol. 79:1990;470-473.
65. Starnes H. F. Jr. Anti-IL-6 monoclonal antibodies protect against lethalEscherichia coli. J. Immunol. 145:1990;4185-4191.
66. May L. T. High levels of "complexed" interleukin-6 in human blood. J. Biol. Chem. 267:1992;19698-19704.
67. May L. T. Antibodies chaperone circulating IL-6. J. Immunol. 151:1993;3225-3236.
68. Barton B. E., Mayer R. IL-3 and IL-6 do not induce bone resorption in vitro. Cytokine. 2:1990;217-220.
69. Al-Humidan A. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J. Bone Miner. Res. 6:1991;3-8.
70. Ishimi Y. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145:1990;3297-3303.
71. Lowik C. W. G. M. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162:1989;1546-1552.
72. 2. Cytokine. 6:1994;368-375.
73. Binkley N. C. Effects of recombinant human interleukin-6 administration on bone in rhesus monkeys. J. Bone Miner. Res. 13:1994;221-226.
74. Most W. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. J. Bone Miner. Res. 10:1995;1523-1530.
75. Girasole G. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:1992;883-891.
76. Miyaura C. Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10:1995;1365-1373.
77. Tamura T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA. 90:1993;11924-11928.
78. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human bone marrow cultures by inducing IL-1 release. J. Immunol. 144:1990;4226-4230.
79. Udagawa N. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182:1995;1461-1468.
80. Roodman G. D. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 89:1992;46-52.
81. Roodman G. D. Biology of the osteoclast in Paget's disease. Semin. Arthritis Rheum. 23:1994;235-236.
82. Hoyland J. A., Freemont A. J., Sharpe P. T., Interleukin-6 IL-. 6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J. Bone Miner. Res. 9:1994;75-80.
83. Strassman G., Fong M., Kenney J. S., Jacob C. O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1992;1681-1684.
84. Strassman G. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia. J. Clin. Invest. 92:1993;2152-2159.
85. Oldenburg H. S. A. Cachexia and the acute-phase response in inflammation are regulated by interleukin-6. Eur. J. Immunol. 23:1993;1889-1894.
86. Strassman G., Fong M., Windsor S., Neta R. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine. 5:1993;285-290.
87. Black K., Garrett I. R., Mundy G. R. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 128:1991;2657-2659.